This secondary analysis of the 24-week SMART study examined the efficacy of add-on saxagliptin or acarbose to metformin across different patient subgroups with type 2 diabetes mellitus (T2DM), based on baseline characteristics.
INTRODUCTION
According to recent estimates from the International Diabetes Federation, China has the highest number of individuals with diabetes worldwide, with a prevalence of 10.9% (114 million) among adults aged years; approximately 90% of these patients have T2DM. 1 The high prevalence of T2DM and the corresponding costs of its associated complications place a considerable strain on China's public health services. [1] [2] [3] The management of T2DM involves optimal control of hyperglycemia through lifestyle modification and drug therapy, with metformin as the preferred choice of monotherapy. 4, 5 The international and national clinical practice guidelines, including the Chinese Diabetes Society (CDS) recommend an HbA1c target of <7% in patients with T2DM. 4, 5 A less stringent target of <8.0% is recommended for patients with a history of severe hypoglycemia, or those with advanced macro-and microvascular complications. 4 The progression of disease eventually necessitates additional glucose-lowering therapies. The CDS recommend insulin secretagogues, α-glucosidase inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, or thiazolidinediones as add-on to metformin. 5 The choice of combination therapy is based on drug-specific and patient characteristics, with emphasis on a patient-centric approach for the management of hyperglycemia. 6 Head-to-head studies comparing different treatment choices provide evidence on potential differences in the efficacy and safety of different drugs and inform the choice of therapy in clinical practice.
The 24-week SMART study, which compared the efficacy and safety of saxagliptin and acarbose as an add-on to metformin in Chinese patients with T2DM, demonstrated the noninferiority of saxagliptin to acarbose for the reduction of HbA1c, with a favorable gastrointestinal safety profile. 7 In this secondary analysis of the SMART study, we sought to examine the impact of baseline age, body mass index (BMI), HbA1c and renal function on the glycemic effects of saxagliptin and acarbose. Identifying the patients who would benefit most from either saxagliptin or acarbose would assist physicians in selecting the optimal second-line therapy according to the individual patient profiles.
METHODS
The design and primary results of the study have been previously described. 7 Briefly, the SMART study (NCT02243176) was a 24-week, multicenter, randomized, parallel-group, open-label Phase IV study that compared saxagliptin with acarbose as second-line therapy in Chinese patients with T2DM inadequately controlled with metformin monotherapy. Male and female patients aged ≥18 years with HbA1c 7.5-11.0% at screening, receiving a stable dose of metformin monotherapy (≥1,500 mg/day or allowed maximum tolerated dose) for at least 8 weeks prior to screening were enrolled in the study. Key exclusion criteria included a history of acute metabolic complications of diabetes within 6 months before screening; fasting triglycerides >4.5 mmol/L, moderate/severe renal impairment at screening or within 4 weeks before screening; or significant cardiovascular history within 3 months before screening.
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Eligible patients were randomized (1:1) to receive saxagliptin (Onglyza ® , AstraZeneca, Möndal, Sweden) 5 mg once daily, or acarbose (Glucobay ® , Bayer AG, Leverkusen, Germany) 50 mg three times daily (uptitrated to 100 mg three times daily if appropriate via telephonic reminder after 7 days following randomization), as an add-on to their existing metformin therapy for 24 weeks. No adjustments in the metformin dose were allowed unless warranted by the risk of hypoglycemia. The primary endpoint was the absolute change in HbA1c at Week 24. Key efficacy parameters (HbA1c, FPG and 2-hour postprandial glucose [2h-PPG]) were blinded for investigators during the randomized phase of the study. The trial was approved by the independent ethics committee at each study center, and all patients provided written informed consent.
Statistical Analysis
For the present analysis to assess the treatment effects on different subgroups of patients with T2DM, randomized patients were classified into subgroups based on their baseline age (<65, ≥65 years), BMI (<24, 24 to <28, ≥28 Kg/m 2 ), HbA1c level (<8%, 8 to <9%, 9 to <10%, ≥10%) and renal function (creatinine clearance [CrCl] mildly impaired [50 to <80 mL/min], normal [≥80 ml/min]). The BMI subgroups were based on cut-offs recommended by the WHO and Chinese Diabetes Society for overweight (≥24 Kg/m 2 ) and obesity (≥28 Kg/m 2 ). 5, 8 In addition, as each 1% change in HbA1c level is clinically meaningful, we categorized the patients based on each 1% increase from the target HbA1c target (<7%). As there were relatively fewer patients in HbA1c ≥10% subgroup, we combined the 9% to <10% and ≥10% subgroups and analyzed the treatment effects across <8%, 8 to <9%, and ≥9% subgroups. The creatinine clearance subgroups were based on the cut-offs used by Gu et al for normal (CrCl >80mL/min) and mild renal impairment (50<CrCl to ≤80 mL/min). 9 The changes from baseline in the HbA1c (primary outcome), FPG, blood pressure (BP) and serum lipid levels (total cholesterol, low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides) were assessed across these subgroups using a mixed-model repeatedmeasures model, adjusting for baseline variables (age or BMI or HbA1c or CrCl), time, and baseline values.
The changes in 2h-PPG and homeostatic model assessment of β-cell function (HOMA-β) were analyzed using analysis of covariance, with baseline variables (age or BMI or HbA1c or CrCl) and baseline values of 2h PPG and HOMA-β as the covariates. The treatment effect was presented as the least squares (LS) mean change (standard error) in outcome measure from baseline to Week 24 for each subgroup.
As both saxagliptin and acarbose primarily affect PPG, multivariate linear regression analyses were conducted to determine the factors associated with the treatment effect on 2h-PPG. In addition, multivariate logistic regression analyses were performed to identify the factors associated with achieving target HbA1c levels <7%. A stepwise regression model was performed using glycemic control (HbA1c <7%) or 2h-PPG as outcome variables for each treatment group, using gender, baseline age, diabetes duration, BMI, HbA1c, FPG, PPG, HOMA-β, insulin, and diabetes-related complications as covariates.
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RESULTS
The SMART study randomized 488 patients with T2DM, of whom 481 received at least one dose of the study medications, and had at least one post-baseline efficacy measure (saxagliptin, n = 238; acarbose, n = 243). At baseline, the mean (SD) age of patients was 55. 6 Table 1 ).
Impact of baseline patient characteristics on glycemic efficacy of saxagliptin
Reductions in HbA1c from baseline to Week 24 (primary endpoint) were consistent across different subgroups defined by baseline age, BMI, HbA1c and renal function, with no significant differences between the subgroups (Figure 1 ). The magnitude of HbA1c reduction with saxagliptin was greater in patients with higher baseline HbA1c levels ( Figure 1A ).
Overall, FPG and PPG were reduced with saxagliptin treatment across all subgroups studied ( Figure 2 ).
The magnitude of FPG reduction was consistent in low (<8%, -1.33 mmol/L) and high baseline HbA1c groups (9-10%, -1.20 mmol/L and ≥10%, -1.17 mmol/L), but was diminished in the 8 to <9% subgroup (-0.64 mmol/L; P = 0.0019 vs. HbA1c <8% subgroup; Figure 2A ). Similarly, the magnitude of FPG-lowering was reduced in the BMI ≥28 Kg/m 2 (P = 0.0175 vs. <24 Kg/m 2 subgroup; Figure 2B ). The effects of saxagliptin on HbA1c, FPG and PPG were consistent when analyzed across the HbA1c subgroups: <8%, 8 to <9% and ≥9% (Supplementary Figure 1A and 1B ).
In the multivariate linear regression analysis, the mean change in 2h-PPG with saxagliptin significantly and positively correlated with BMI (regression coefficient: +0.175; P ≤0.001) and duration of diabetes (+0.104; P = 0.010). Also, the change in 2h-PPG significantly correlated with baseline HbA1c (-0.642; P = 0.008), baseline PPG (-0.633; P <0.001) and insulin levels (-0.039; P = 0.028), indicating a greater reduction in PPG with higher baseline levels of HbA1c, PPG and insulin (Supplementary Table 2 ). In addition, increases in HOMA-β with saxagliptin treatment were consistent across most subgroups studied (Supplementary Figure 2 ).
Impact of baseline patient characteristics on glycemic efficacy of acarbose
The changes in HbA1c at Week 24 were consistent across subgroups based on baseline age, BMI and renal function ( Figure 3 ); however, in the subgroup defined by baseline HbA1c, the magnitude of reduction was lower in patients with baseline HbA1c ≥10% compared to <8% (LS mean change from baseline: -0.07% versus -0.71%, respectively); however, this difference was not statistically significant ( Figure 3 ).
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The efficacy of acarbose on FPG diminished progressively at higher baseline HbA1c levels, with an increase in FPG observed in patients with baseline HbA1c of 9 to <10% and ≥10% ( Figure 4A ). Changes in FPG were significantly different between lower and higher HbA1c subgroups: <8% (-1.43 mmol/L), 8 to <9% (-0.92 mmol/L; P = 0.0139), 9 to <10%, (+0.10 mmol/L; P <0.0001) and ≥10% (+0.86; P = 0.0005).
Similarly, the effects of acarbose on PPG varied across HbA1c subgroups. Compared to the HbA1c <8% group, the decrease in PPG was lower in patients with baseline HbA1c 8 to <9%, and the difference between the subgroups tended to approach statistical significance (−0.49 mmol/L versus −1.25 mmol/L; P = 0.0527). In patients with baseline HbA1c 9 to <10%, there was an increase in PPG levels from baseline to Week 24 (+0.23 versus -1.25 mmol/L in those with baseline HbA1c <8%; P = 0.0092) ( Figure 4 ). In an analysis by subgroups <8%, 8 to <9% and ≥9%, the effects of acarbose on FPG and PPG were significantly and progressively attenuated in patients with HbA1c ≥8% (P <0.05 for all comparisons;
Supplementary Figure 1D ).
In the multivariate linear regression analysis, mean change in 2h-PPG with acarbose was significantly and directly correlated with the duration of diabetes (regression coefficient: +0.081; P = 0.032), and inversely correlated with baseline PPG (-0.714; P <0.001) (Supplementary Table 2 ). In addition, acarbose treatment was associated with an increase in HOMA-β across the majority of subgroups studied (Supplementary Figure 3 ).
Predictors of achievement of glycemic target (HbA1c <7%)
For patients treated with saxagliptin, the duration of diabetes, baseline HbA1c, FPG, and 2h-PPG levels were significant negative factors by univariate analysis (P <0.01); Table 1 . However, only the duration of diabetes and HbA1c levels were significant factors by multivariate analysis (P <0.05; Table 1 ).
For patients treated with acarbose, baseline HbA1c, FPG, and 2h-PPG levels were significant negative factors by univariate analysis (P = 0.000), whereas only HbA1c and FPG were significant factors by multivariate analysis (P ≥0.008).
Hemodynamic and metabolic effects of saxagliptin and acarbose
Saxagliptin therapy was associated with a decrease in systolic and diastolic BP from baseline values across the majority of subgroups; however, the magnitude of BP reduction was lower in older patients and in those with higher BMI (Supplementary Table 3 ). In addition, there was a decrease from baseline in total cholesterol and LDL-C levels, and a slight increase in triglycerides across most subgroups (Supplementary Table 3 ).
Treatment with acarbose was associated with a decrease from baseline in BP, total cholesterol and LDL-C levels across most of the subgroups. The treatment effect on total cholesterol and LDL-C varied for patients with higher baseline HbA1c levels, with a slight increase from baseline observed in patients with baseline HbA1c ≥10% (Supplementary Table 2 ).
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DISCUSSION
The 24-week SMART study has previously demonstrated the noninferiority of saxagliptin to acarbose for glycemic control in Chinese patients with T2DM inadequately controlled on metformin monotherapy. 7 This post-hoc analysis of the SMART study demonstrated that saxagliptin is associated with a stable control of hyperglycemia (HbA1c, FPG, and PPG) across a range of patient subgroups regardless of baseline HbA1c, age, BMI, and renal function. On the other hand, acarbose therapy was associated with a reduction in HbA1c across most of the subgroups studied; however, the decrease in HbA1c was attenuated in patients with baseline HbA1c ≥10%. In addition, the efficacy of acarbose on FPG and PPG was progressively and significantly attenuated in patients with baseline HbA1c ≥8%, with an increase from baseline FPG levels observed in patients with baseline HbA1c ≥9%.
The efficacy and safety of saxagliptin as monotherapy or combination therapy in Chinese patients with T2DM have been established in several studies. [9] [10] [11] [12] In the present study, saxagliptin as add-on to metformin has demonstrated consistent glycemic efficacy across a range of patient profiles. These results are similar to those observed in the SUNSHINE trial, which demonstrated consistent glycemic efficacy of saxagliptin across subgroups stratified by baseline age, CrCl, BMI, HbA1c, and treatment status (drug-naïve or metformin uncontrolled). 9 The efficacy of glucose-lowering therapies across the HbA1c spectrum is particularly important, as baseline HbA1c is an independent predictor of the likelihood of achieving glycemic control. A meta-regression analysis of 78 randomized controlled trials with 20,053 patients showed that DPP-4 inhibitors have greater efficacy in reducing HbA1c in patients with higher baseline values, with a 0.26% incremental reduction in the HbA1c response for every 1% increase of baseline HbA1c (P <0.001). 13 Similar results were reported in the SUNSHINE and SPECIFY trials in Chinese patients with T2DM. 9, 12 In the SUNSHINE trial, saxagliptin treatment was associated with larger reductions in HbA1c in patients with higher baseline values -the reductions in HbA1c ranged from -0.78% in patients with baseline HbA1c of <8.0% to -2.90% in those with baseline HbA1c ≥10.0% to ≤11%. 9 In the 48-week SPECIFY trial, the reductions in HbA1c with saxagliptin therapy ranged from -0.56% to -1.80% in patients with baseline HbA1c <8.0% and ≥9.0%, respectively. 12 In the present analysis, the reductions in HbA1c were numerically larger in patients with higher baseline HbA1c values, ranging from -0.77% in patients with HbA1c <8.0% to -1.16% in those with HbA1c ≥10.0%.
Furthermore, saxagliptin therapy reduced FPG and PPG across all subgroups. The magnitude of FPG reduction was lower in patients with baseline HbA1c 8 to <9% (vs. HbA1c <8% subgroup), however, this may not be clinically relevant as there was no clear trend in the attenuation of effects on FPG in patients with higher baseline HbA1c (≥9% subgroups). In addition, the magnitude of FPG-lowering with saxagliptin was reduced in patients with BMI ≥28 Kg/m 2 (vs. <24 Kg/m 2 subgroup). This discrepancy in FPG-lowering effect was not observed previously in the SUNSHINE study with a larger sample size (N=1423), which showed a consistent reduction in FPG across all BMI subgroups (≥28 Kg/m 2 , −0.49 mmol/L; ≥24 to <28 Kg/m 2 , −0.62 mmol/L; <24 Kg/m 2 , −0.50 mmol/L). 9 In addition, a pooled analysis of five randomized clinical trials (N=1994) revealed no association between BMI and glycemic response to saxagliptin treatment. 14 
On
Accepted Article the other hand, a meta-analysis of 55 studies by Kim et al, showed a significant correlation between the HbA1c-loweing effect of DPP-4 inhibitors and baseline BMI, especially in studies with average BMI <30 kg/m 2 ; however, this was not observed for studies with average BMI ≥30 kg/m 2 . 15 As multiple factors may affect the efficacy of DPP-4 inhibitors (such as β-cell function, GLP-1 release, DPP-4 activity, glucose uptake, and glucagon suppression), these effects cannot be explained by BMI alone. The clinical markers of insulin sensitivity such as abdominal adiposity would provide further insights, however, this information was not available from the current study. Furthermore, the discrepancy in FPG-lowering effect of saxalgliptin across BMI subgroups subgroup could be due to the smaller sample size of the current study.
The efficacy of acarbose on HbA1c was consistent across subgroups defined by baseline age, BMI and renal function. However, there was a numerically smaller reduction in HbA1c for patients with baseline HbA1c ≥10%, which is a more clinically meaningful cut-off for those receiving combination therapy. The
HbA1c reduction was -0.71% in patients with a baseline value <8.0% and -0.07% in those with a baseline value ≥10.0%. The attenuation of HbA1c-lowering efficacy was not observed when patients in high HbA1c were combined (9 to <10% and ≥10%) (Supplementary Figure 1C) , which suggests the variability in treatment effects with every 1% rise in HbA1c levels. These results are in contrast with previous findings from the MARCH trial, which showed larger reductions in HbA1c in patients with higher baseline HbA1c values (<7%, 7-8%, and >8%) with acarbose as initial therapy in newly diagnosed Chinese patients with T2DM. 16 This could perhaps be due to the lack of patients with high baseline HbA1c in the MARCH trial. In addition, the trial enrolled treatment-naïve patients and evaluated the efficacy of acarbose as monotherapy.
The examination of effects on blood glucose levels across different HbA1c subgroups provide further insights. There was a progressive and significant attenuation in the efficacy of acarbose on FPG and PPG levels in patients with higher baseline HbA1c, with an increase in FPG levels observed in patients with HbA1c ≥9% -the LS mean changes from baseline in FPG values ranged from were -1.43 to +0.86 across the HbA1c subgroups. This is in line with the previous observation from the MARCH trial in which acarbose decreased PPG more effectively than metformin only in patients with low or moderate baseline HbA1c (≤8%). 17 The importance of PPG in the management of hyperglycemia is well established, particularly in Asian patients who are more likely to exhibit postprandial hyperglycemia. As both saxagliptin and acarbose decrease PPG, we also conducted a multivariate linear regression analysis to identify factors associated with treatment effects on PPG. For the saxagliptin group, the change in PPG was independently and inversely correlated with baseline PPG and insulin levels, indicating a higher reduction in PPG with an increase in baseline PPG and insulin levels. On the other hand, the change in PPG with acarbose inversely correlated with baseline PPG, indicating a higher reduction in PPG with an increase in baseline PPG.
The current study also showed discordance between the effect of acarbose on HbA1c and plasma glucose levels. This could be partly explained by the glycemic variability as HbA1c levels do not indicate the stability of glycemic control. The glycation of hemoglobin is a nonenzymatic and slow process and is directly proportional to the time-averaged concentration of glucose. 18, 19 Therefore, glycemic fluctuations with Accepted Article intermittent excursions in blood glucose levels may not have a significant impact on HbA1c levels. 20 The glycemic effects of saxagliptin are mediated by glucose-dependent stimulation of insulin secretion and suppression of glucagon, 21 which has been shown to effectively control the glycemic variability. [22] [23] [24] [25] While acarbose has also shown to reduce several parameters of glycemic variability, 26, 27 the current study showed that its efficacy on blood glucose levels appears to diminish at higher baseline HbA1c levels. This could be due to its non-insulin dependent mechanism of action, which is non-systemic and limited to delaying the intestinal glucose absorption and is therefore, independent of the baseline hyperglycemia. In addition, α-glucosidase inhibitors have no effect on the endogenous glucose production, which increases with higher insulin resistance. This may explain the diminished or no effect of acarbose on FPG and PPG in patients with higher baseline HbA1c levels. Taken together, these results suggest a limited utility of acarbose as an add-on to metformin, with beneficial effects observed only in patients with low HbA1c.
There were no clear trends for the treatment effects on lipid profile and blood pressure. Both saxagliptin and acarbose treatments were associated with slight reductions in total cholesterol and LDL-C and increases in HDL-C and triglyceride levels across most subgroups. There are mixed reports on the effects of DPP-4 inhibitors on lipid profile, with slight improvement to no effect on triglyceride levels. [28] [29] [30] In previous studies on patients with T2DM, saxagliptin was not associated with any significant changes in triglyceride levels. 31, 32 Although study data were collected prospectively, the reported analyses were performed post-hoc and, therefore, subject to the potential biases inherent to such analyses. The randomization in the SMART trial was not stratified according to baseline age, HbA1c, BMI and renal function; therefore, the distribution of patients varied across these subgroups. However, the distribution of patients across the different subgroups were comparable between the treatment groups. This analysis was not designed or powered to evaluate the differences in treatment effects across the subgroups and hence the results are exploratory in nature. The evaluation of treatment effects across these subgroups in a larger sample size would provide further evidence on the observed differences. Despite these limitations, this study was the first to compare the efficacy of saxagliptin and acarbose across a range of patient subgroups. The clinical characteristics such as age, BMI, baseline HbA1c, and renal function are key patient factors that help in identifying the most appropriate therapy. The findings from this study will further diversify the clinical evidence to physicians for the selection of optimal second-line treatment for T2DM patients.
In summary, we conducted this study to determine the glycemic effects of saxagliptin and acarbose as an add-on to metformin across a range of patient profiles defined by key baseline characteristics. The study demonstrated that while saxagliptin and acarbose reduced HbA1c regardless of baseline HbA1c, age, BMI, and renal function, only saxagliptin was effective at stable glycemic control (as reflected by control of FPG and PPG). The efficacy of acarbose on FPG and PPG was progressively and significantly attenuated in patients with higher baseline HbA1c (≥8%). Supplementary Table 1 . Patient distribution in the saxagliptin and acarbose arms stratified by baseline characteristics BMI, body mass index; HbA1c, glycated hemoglobin.
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FIGURES LEGENDS
SUPPORTING INFORMATION
Supplementary Table 2. Linear regression analysis for risk factors of change from baseline for 2hour PPG (mmol/L) at Week 24 in patients with T2DM by univariate and multivariate analyses
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BMI, body mass index; CI, confidence interval; FPG, fasting plasma glucose; HbA1c, glycated hemoglobin;
HOMA-β, homeostatic model assessment of β-cell function; OR, odds ratio; PPG, postprandial glucose; T2DM, type 2 diabetes mellitus. Supplementary Table 3 
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